Phase 1
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
- This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
Status: Recruiting
Trial DetailsPhase 1b
A Phase 1b Study of SDX-7320 in Combination with Approved Anti-Cancer Agents to Assess Safety in Patients with Metastatic Breast Cancer
- This is a multicenter Phase 1b study to assess the safety, tolerability and efficacy of subcutaneously administered SDX-7320 in combination with the standard dose and schedule of approved anti-cancer treatments in postmenopausal women with advanced HR+/HER2- metastatic breast cancer and suspected metabolic dysfunction who have progressed after an initial treatment regimen of hormone therapy with or without a targeted therapy.
- Other selected, advanced, metabolically-sensitive solid tumor types will be considered for separate treatment arms in both men and women.
Status: Planned for Q3 2018